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Summary 
Machado–Joseph disease is the most frequently found dominantly-inherited cerebellar 
ataxia. Over-repetition of a CAG trinucleotide in the MJD1 gene translates into a 
polyglutamine tract within the ataxin 3 protein, which upon proteolysis may trigger 
Machado–Joseph disease. We investigated the role of calpains in the generation of toxic 
ataxin 3 fragments and pathogenesis of Machado–Joseph disease. For this purpose, we 
inhibited calpain activity in mouse models of Machado–Joseph disease by 
overexpressing the endogenous calpain-inhibitor calpastatin. Calpain blockage reduced 
the size and number of mutant ataxin 3 inclusions, neuronal dysfunction and 
neurodegeneration. By reducing fragmentation of ataxin 3, calpastatin overexpression 
modified the subcellular localization of mutant ataxin 3 restraining the protein in the 
cytoplasm, reducing aggregation and nuclear toxicity and overcoming calpastatin 
depletion observed upon mutant ataxin 3 expression. Our findings are the first in vivo 
proof that mutant ataxin 3 proteolysis by calpains mediates its translocation to the 
nucleus, aggregation and toxicity and that inhibition of calpains may provide an 
effective therapy for Machado–Joseph disease. 
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Introduction 
Machado–Joseph disease, also known as spinocerebellar ataxia type 3, was originally 
described in people of Portuguese descent and is now considered to be the most 
frequent form of the autosomal dominantly inherited cerebellar ataxias. Machado–
Joseph disease is a neurodegenerative disorder characterized by abnormal movement 
(Sudarsky and Coutinho, 1995) and is caused by an unstable and expanded 
polyglutamine repeat of >55 CAGs within the coding region of the causative gene, 
MJD1, on chromosome 14q32.1 (Kawaguchi et al., 1994), conferring a toxic gain of 
function to the ubiquitin-binding protein ataxin 3 (ATXN3) (Rubinsztein et al., 1999; 
Wang et al., 2000; Burnett et al., 2003; Doss-Pepe et al., 2003; Scheel et al., 2003; Chai 
et al., 2004). 
Ataxin 3 is a protein of ∼42 kDa and is predominantly expressed cytoplasmatically 
(Paulson et al., 1997a; Schmidt et al., 1998), even though it is small enough to enter the 
nucleus through passive diffusion (Marfori et al., 2011). Upon polyglutamine 
expansion, in spite of the increase in its molecular weight which could hinder access to 
the nucleus, mutant ataxin 3 accumulates in ubiquitinated intranuclear inclusions 
(Paulson et al., 1997b). The toxic fragment hypothesis predicts that proteolytic cleavage 
of the full-length polyglutamine protein initiates the aggregation process associated with 
inclusion formation and cellular dysfunction (Haacke et al., 2006; Takahashi et al., 
2008). 
A toxic cleavage fragment of mutant ataxin 3 was first proposed to trigger 
neurodegeneration by Ikeda et al. (1996). Indeed, the C-terminal fragment of mutant 
ataxin 3 is more toxic than the full-length protein (Ikeda et al., 1996; Paulson et al., 
1997b; Goti et al., 2004). Understanding the proteolytic mechanism involved and the 
cellular protease(s) responsible could unravel the trigger mechanism for Machado–
Joseph disease and reveal potential targets for therapy. Haacke and colleagues observed 
in cell lysates that upon calcium influx, ataxin 3 was proteolysed by calpains in 
fragments that could escape cytoplasmic quality control (Haacke et al., 2007; Breuer et 
al., 2010). This observation was recently confirmed in patient specific induced 
pluripotent stem cell-derived neurons (Koch et al., 2011). Calpain regulation is 
therefore critical and can come about by binding to calpastatin, the only endogenous 
calpain-specific inhibitor identified thus far (Takano et al., 2005). How ataxin 3 
cleavage fragments mediate neurotoxicity has not been evaluated in animal models of 
Machado–Joseph disease. Overactivation of calpains may contribute decisively to the 
pathology by increasing cleavage of ataxin 3 into fragments containing the expanded 
polyglutamine segment, which may be able to penetrate the nuclear pore, accumulate in 
the nucleus and induce neurodegeneration. 
Herein, taking advantage of adeno-associated (AAV) viral vectors for overexpression of 
calpastatin, we set out to investigate in a lentiviral mouse model of Machado–Joseph 
disease (Alves et al., 2008) and transgenic mice overexpressing calpastatin (Takano et 
al., 2005) whether and how calpains are involved in the pathogenesis of the disease. We 
provide in vivo evidence that: (i) proteolysis by calpains is required for nuclear 
localization of mutant ataxin 3; (ii) inhibition of calpains significantly decreases 
neuronal dysfunction and neurodegeneration in a mouse model of Machado–Joseph 
disease; (iii) production of mutant ataxin 3 cleavage fragments and the resulting nuclear 
localization inversely correlate with calpastatin levels in a dose-dependent manner; and 
(iv) calpastatin is depleted from neurons bearing mutant ataxin 3 intranuclear 
inclusions. In conclusion, we provide new insights into mutant ataxin 3 proteolysis, 
nuclear translocation and a resulting role in the pathogenesis of Machado–Joseph 
disease, which indicate that calpain inhibition may provide a new avenue of therapy. 
Materials and methods 
Animals 
Four-week-old C57BL/6J mice (Charles River) were used. The animals were housed in 
a temperature-controlled room maintained on a 12 h light/12 h dark cycle. Food and 
water were provided ad libitum. The experiments were carried out in accordance with 
the European Community directive (86/609/EEC) for the care and use of laboratory 
animals. The researchers received adequate training (Felasa-certified course) and 
certification to perform the experiments from the Portuguese authorities (Direcção Geral 
de Veterinária). 
Human brain tissue 
Post-mortem human brain tissue from dentate nucleus was obtained from the tissue 
donation program of the National Ataxia Foundation, Minneapolis, MN, USA (VA 
Medical Centre and Albany Medical College). The tissues included a control patient 
(female, 36 years) and three patients with Machado–Joseph disease: Patient O (female, 
70 years, 67/23 CAG repeats); Patient W (female, 62 years, 74/22 CAG repeats); and 
Patient K (male, 53 years, 69/23 CAG repeats). 
Machado–Joseph disease transgenic mice tissue 
Cerebella of Machado–Joseph disease transgenic mice (5.5 and 15 weeks old, n = 2 and 
n = 4, respectively) (Torashima et al., 2008; Oue et al., 2009) expressing a truncated 
form of human ataxin 3 with 69 CAG repeats, and wild-type mice (n = 3; 20 weeks old) 
of an older offspring were dissected and treated for western blot analysis. 
Production of viral vectors 
Lentiviral vectors encoding human wild-type ataxin 3 (ATX-3 27Q) or mutant ataxin 3 
(ATX-3 72Q) (Alves et al., 2008) were produced in 293T cells with a four-plasmid 
system, as previously described (de Almeida et al., 2001). The lentiviral particles were 
resuspended in 1% bovine serum albumin in PBS. The viral particle content of batches 
was determined by assessing HIV-1 p24 antigen levels (Retro Tek, Gentaur). Viral 
stocks were stored at −80°C. 
AAV vectors were produced as previously described (Zolotukhin et al., 1999; Kugler et 
al., 2003). 
In vivo injection into the striatum 
Concentrated viral stocks were thawed on ice. Lentiviral vectors encoding human wild-
type (ATX-3 27Q) or mutant ataxin 3 (ATX-3 72Q) were stereotaxically injected into 
the striatum at the following coordinates: antero-posterior: +0.6 mm; lateral: ±1.8 mm; 
ventral: −3.3 mm; tooth bar: 0. Animals were anaesthetized by administration of avertin 
(10 µl/g intraperitoneally). 
Wild-type and transgenic mice overexpressing calpastatin received a single 1 µl 
injection of 0.2 mg p24/ml lentivirus in each side: left hemisphere (ATX-3 27Q) and 
right hemisphere (ATX-3 72Q). Wild-type mice were co-injected with 1 µl of 0.4 mg 
p24/ml ataxin 3 72Q lentivirus and 3 µl of AAV1/2-green fluorescent protein (AAV1/2-
GFP; left hemisphere) or AAV2-calpastatin (AAV2-CAST; right hemisphere). 
For the western blot procedure, transgenic mice overexpressing calpastatin received a 
single 2 µl injection of 0.3 mg p24/ml lentivirus in each side: left hemisphere (ATX-3 
27Q) and right hemisphere (ATX-3 72Q). Wild-type mice were co-injected with 1 µl of 
0.6 mg of p24/ml ATX-3 72Q lentivirus and 4 µl of AAV1/2-GFP (left hemisphere) or 
AAV2-CAST (right hemisphere). 
Mice were kept in their home cages for 4, 5 or 8 weeks before being sacrificed for 
immunohistochemical or western blot analysis. 
Imunohistochemical procedure 
After an overdose of avertin (2.5 times, 12 µl/g given intraperitoneally), transcardial 
perfusion of the mice was performed with a phosphate solution followed by fixation 
with 4% paraformaldehyde. The brains were removed and post-fixed in 4% 
paraformaldehyde for 24 h and cryoprotected by incubation in 25% sucrose/phosphate 
buffer for 48 h. The brains were frozen and 25 µm coronal sections were cut using a 
cryostat (LEICA CM3050 S) at −21°C. Slices throughout the entire striatum were 
collected in anatomical series and stored in 48-well trays as free-floating sections in 
PBS supplemented with 0.05 µM sodium azide. The trays were stored at 4°C until 
immunohistochemical processing. 
Sections from injected mice were processed with the following primary antibodies: a 
mouse monoclonal anti-ataxin 3 antibody (1H9; 1:5000; Chemicon), recognizing the 
human ataxin 3 fragment from amino acids F112 to L249; a rabbit polyclonal anti-
ubiquitin antibody (Dako, 1:1000); a mouse monoclonal anti-myc tag antibody, clone 
4A6 (1:1000; Upstate, Cell Signalling Solutions); and a rabbit anti- dopamine- and 
cyclic AMP-regulated neuronal phosphoprotein (DARPP-32) antibody (1:1000; 
Chemicon), followed by incubation with the respective biotinylated secondary 
antibodies (1:200; Vector Laboratories). Bound antibodies were visualized using the 
VECTASTAIN® ABC kit, with 3,3′-diaminobenzidine tetrahydrochloride (DAB metal 
concentrate; Pierce) as substrate. 
Double stainings for ataxin 3 (1H9; 1:3000), nuclear marker [DAPI (4′,6-diamidino-2-
phenylindole), blue] and ubiquitin (Dako, 1:1000) or calpastatin (H300, 1:250, Santa 
Cruz) were performed. Free-floating sections from injected mice were incubated at 
room temperature for 2 h in PBS/0.1% Triton™ X-100 containing 10% normal goat 
serum (Gibco), and then overnight at 4°C in blocking solution with the primary 
antibodies. Sections were washed three times and incubated for 2 h at room temperature 
with the corresponding secondary antibodies coupled to fluorophores (1:200, Molecular 
Probes) diluted in the respective blocking solution. The sections were washed three 
times and then mounted in FluorSave™ Reagent (Calbiochem) on microscope slides. 
Staining was visualized using Zeiss Axioskop 2 plus, Zeiss Axiovert 200 and Zeiss 
LSM 510 Meta imaging microscopes (Carl Zeiss Microimaging), equipped with 
AxioCam HR colour digital cameras (Carl Zeiss Microimaging) using 5×, 20×, 40× and 
63× Plan-Neofluar and a 63× Plan/Apochromat objectives and the AxioVision 4.7 
software package (Carl Zeiss Microimaging). 
Quantitative analysis of fluorescence was performed with a semi-automated image-
analysis software package (ImageJ software). 
Cresyl violet staining 
Coronal 25 µm thick striatal sections were cut using a cryostat. Pre-mounted sections 
were stained with cresyl violet for 30 s, differentiated in 70% ethanol, dehydrated by 
passing twice through 95% ethanol, 100% ethanol and xylene solutions and mounted 
onto microscope slides with Eukitt® (Sigma). 
Evaluation of the volume of the dopamine- and cAMP-regulated neuronal 
phosphoprotein depleted volume 
The extent of ataxin 3 lesions in the striatum was analysed by photographing, with a 
1.25× objective, eight DARPP-32 stained sections per animal (25 µm thick sections at 
200 µm intervals), selected to obtain complete rostrocaudal sampling of the striatum, 
and by quantifying the area of the lesion with a semi-automated image analysis software 
package (ImageJ). The volume was then estimated with the following formula: volume 
= d(a1 + a2 + a3…), where d is the distance between serial sections (200 µm) and a1 + a2 
+ a3 are DARPP-32 depleted areas for individual serial sections (de Almeida et al., 
2002). 
Cell counts and morphometric analysis of ataxin 3 and ubiquitin 
inclusions 
Coronal sections showing complete rostrocaudal sampling (one of eight sections) of the 
striatum were scanned with a 20× objective. The analysed areas of the striatum 
encompassed the entire region containing ataxin 3 and ubiquitin inclusions, as revealed 
by staining with the anti-ataxin 3 and anti-ubiquitin antibodies. All inclusions were 
manually counted using a semiautomated image-analysis software package (ImageJ). 
Inclusions diameter was assessed by scanning the area above the needle tract in four 
different sections, using a 63× objective. At least 100 inclusions showing double 
staining for mutant ataxin 3 and GFP or calpastatin were analysed using LSM Image 
Browser. 
Western blot analysis 
For assessment of ataxin 3 proteolysis in the lentiviral model of Machado–Joseph 
disease, transcardial perfusion of the mice was performed with ice-cold PBS containing 
10 mM EDTA (ethylenediaminetetraacetic acid) and 10 mM of the alkylating reagent 
N-ethylmaleimide, to avoid post-mortem calpain overactivation. The injected striata 
were then dissected and immediately sonicated in radioimmunoprecipitation assay 
buffer [50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 7 mM EDTA, 1% NP-40 (nonyl 
phenoxypolyethoxylethanol), 0.1% SDS, 10 µg/ml DTT (dithiothreitol), 1 mM PMSF 
(phenylmethylsulphonyl fluoride), 200 µg/ml leupeptin, protease inhibitors cocktail]. 
Equal amounts (30 µg of protein) were resolved on 12% SDS–PAGE and transferred 
onto PVDF (polyvinylidene fluoride) membranes. Immunoblotting was performed using 
the monoclonal anti-ataxin 3 antibody (1H9, 1:1000; Chemicon), anti-calpastatin 
(H300, 1:200; Santa Cruz), anti-calpain-cleaved α-spectrin (Roberts-Lewis et al., 1994) 
(Ab 38, 1:3000) and anti-actin (clone AC-74, 1:5000; Sigma) or anti-tubulin (clone 
SAP.4G5, 1:15 000; Sigma). A partition ratio with actin or tubulin was calculated 
following quantification with Quantity One® 1-D image analysis software version 4.5. 
Statistical analysis 
Statistical analysis was performed using Student’s t-test or ANOVA for multiple 
comparisons. Values of P < 0.05 were considered statistically significant. 
Results 
Inhibition of calpains in a lentiviral mouse model of Machado–Joseph 
disease reduces the size and number of neuronal intranuclear inclusions 
of mutant ataxin 3 
In order to investigate the role of calpains in the pathogenesis of spinocerebellar ataxia 
type 3, we overexpressed the calpain inhibitor calpastatin in a lentiviral mouse model of 
Machado–Joseph disease (Alves et al., 2008). Four-week-old mice were co-injected 
bilaterally in the striatum with lentiviral vectors encoding ATX-3 72Q and AAV vectors 
encoding GFP (control, left hemisphere) or calpastatin (right hemisphere; Fig. 1) and 
were sacrificed 8 weeks post-injection. Mice singly injected with calpastatin and GFP 
were used as a control of AAV transduction. AAV vectors mediate a delayed expression 
of calpastatin, when compared with a quicker onset of ataxin 3 expression upon 
lentiviral transduction, due to the necessity of conversion of the single-stranded genome 
into double stranded DNA, especially in non-dividing cells (Shevtsova et al., 2005). 
Therefore, co-injection of both viral vectors in the mouse brain allowed cells co-
transduction in a phased manner, leading to the development of pathology before 
maximum expression of the calpain inhibitor 2 weeks later.  
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Figure 1  
Strategy used to generate an in vivo mouse model of Machado–Joseph disease and to 
inhibit mutant ataxin 3 proteolysis by calpains. Schematic representation of the 
lentiviral (LV) constructs used in the development of the mouse model of Machado–
Joseph disease. Complementary DNAs encoding (A) wild-type (27 CAG repeats) or 
(B), mutant ataxin 3 (72 CAG repeats) were cloned in the SIN-W transfer vector. (C) 
Schematic of the AAV1/2 encoding GFP. (D) The complementary DNA encoding 
calpastatin was inserted into an AAV serotype 2 backbone, under the control of the 
human synapsin 1 gene promoter, which restrains expression to neurons. (E) Four-
week-old mice were co-injected bilaterally in the striatum with ATX3-72Q and GFP 
(left hemisphere) or calpastatin (right hemisphere) vectors and were sacrificed 5 and 8 
weeks post-injection for western blot and immunohistochemical analysis, respectively 
(injection co-ordinates: antero-posterior: +0.6 mm; lateral: ±1.8 mm; ventral: −3.5 mm; 
tooth bar: 0). (F) Diagram of ataxin 3 showing antibody recognition sites used in Fig. 5. 
hSYN = human synapsin 1; ITR = inverted terminal repeat; LTR = long terminal repeat; 
NES = nuclear export signal; NLS = nuclear localization signal; PGK = 
phosphoglycerate kinase. 
Calpain inhibition by calpastatin reduced the size and number of mutant ataxin 3 (ATX-
3 72Q) inclusions (Figs 2B, D and K and 4
hemisphere (Figs 2A, C and K and 4E). In this control hemisphere (Fig. 2C) and in cells 
not infected by calpastatin (Fig. 2D; arrowhead), ATX-3 72Q accumulated in large 
intranuclear inclusions with 3.98 µm mean diameter and co-localized with ubiquitin 
(Fig. 2E–G). On the contrary, upon calpastatin overexpression, mutant ataxin 3 
inclusions became very small, almost undetectable by fluorescence 
immunohistochemistry (Fig. 2D), and ubiquitin pattern was diffuse (Fig. 2H–J). Calpain 
inhibition promoted a 2.9-fold reduction in inclusions diameter to 1.4 µm (Figs 2C and 
D and 4E) and reduced to 47% the number of N-terminal ataxin 3 inclusions detected 
with an anti-myc antibody (Fig. 2A, B and K), an effect that was less prominent when 
inclusions were counted in brightfield upon imunohistochemistry with the 1H9 
(recognizes amino acids 221–224) or anti-ubiquitin antibodies (data not shown). This 
may be due to the fact that the C-terminal of ataxin 3, including the polyglutamine tract, 
is more prone to aggregation.  
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Figure 2  
Inhibition of calpains significantly decreases the number of N-terminal mutant ataxin 3 
inclusions, while changing mutant ataxin 3 and ubiquitin aggregation pattern. (A–K) 
Co-expression of mutant ataxin 3 and GFP (left hemisphere) or calpastatin (right 
hemisphere) in the striatum of adult mice, 2 months post-injection. (A and B) 
Peroxidase staining using an anti-myc antibody to the myc tag of the N-terminal ataxin 
3 (Ab clone 4A6). A significant decrease in the number of N-terminal ataxin 3 
inclusions was observed in calpastatin transduced hemisphere. (C) Fluorescence 
staining for mutant ataxin 3 (Ab 1H9, red) localization upon co-expression with GFP 
(green) or (D) calpastatin (Ab H300, green). Nuclear marker (DAPI, blue) was used. As 
expected, in the GFP transduced hemisphere mutant ataxin 3 was observed as 
intranuclear inclusions. On the contrary, the cells infected with AAV2-calpastatin 
showing calpastatin immunoreactivity, presented small inclusions almost not depicted. 
(E–G) Fluorescence staining for co-localization (G and J) merge of E and F or H and I 
with nuclear marker DAPI (blue) of mutant ataxin 3 (E and H, Ab 1H9, green) and 
ubiquitin (F and I, antibody anti-ubiquitin DAKO, red). While in the control 
hemisphere mutant ataxin 3 intranuclear inclusions (E) were ubiquitinated (F) 
particularly within the central core, (H–J) ubiquitin pattern upon calpastatin 
overexpression was rather diffuse. (K) Quantification of the absolute number of myc-
positive cells, graph related to panels (A and B). Statistical significance was evaluated 
with Student’s t-test (n = 4, *P = 0.05). SEM = standard error of the mean, CAST = 
calpastatin. 
Upon co-infection with vectors encoding wild-type ataxin 3 (ATX-3 27Q) and GFP (left 
hemisphere) or calpastatin (right hemisphere; Fig. 1), neither ataxin 3 nor ubiquitin 
inclusions were observed. Furthermore, no difference in the subcellular localization of 
ATX-3 27Q was observed between the two hemispheres (data not shown). 
These results suggest that inhibition of calpain activity in the mouse brain prevents 
accumulation of mutant ataxin 3 in large intranuclear inclusions. 
Inhibition of calpains in a lentiviral mouse model of Machado–Joseph 
disease mediates striatal neuroprotection 
To monitor the effects of calpastatin overexpression over neuronal dysfunction induced 
by mutant ataxin 3 we performed an immunohistochemical analysis for DARPP-32, a 
regulator of dopamine receptor signalling (Greengard et al., 1999) which we have 
previously shown to be downregulated in the striatum of lentiviral and transgenic 
Machado–Joseph disease animal models (Alves et al., 2008). Loss of DARPP-32 
immunoreactivity in the calpastatin injected striatal hemisphere was reduced to 39% 
when compared with the GFP transduced hemisphere (Fig. 3A–D and G), whereas no 
loss of DARPP-32 staining was detected in mice co-injected with ATX-3 27Q and GFP 
or calpastatin (data not shown). This is indicative of a neuroprotective effect provided 
by the selective inhibition of calpains.  
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Figure 3  
Inhibition of calpains prevents cell injury and striatal degeneration. (A–H) Co-
expression of mutant ataxin 3 (ATX-3 72Q) and GFP (left hemisphere) or calpastatin 
(CAST, right hemisphere) in the striatum of adult mice, 2 months post-injection. (A–D) 
Peroxidase staining using an anti-DARPP-32 antibody. (C and D) Higher magnification 
of A and B. (A and C) A major loss of DARPP-32 immunoreactivity was observed in 
the striatum infected with ATX-3 72Q and GFP (B and D), whereas minor DARPP-32 
loss was observed in the striatum infected with ATX-3 72Q and calpastatin. (E and F) 
Cresyl violet staining of (E) ATX-3 72Q + GFP and (F) ATX-3 72Q + calpastatin 
transduced hemispheres of adult mice. (G) Quantification analysis of the DARPP-32-
depleted region in the brains of mice. The lesion volume in the hemisphere infected 
with ATX-3 72Q and calpastatin was much smaller than that in the hemisphere infected 
with ATX3-72Q and GFP, indicative of a neuroprotective effect conferred by the 
inhibition of calpains (n = 4, *P = 0.05). (H) Quantification analysis of the pyknotic 
nuclei visible in both hemispheres on cresyl violet-stained sections. More pyknotic 
nuclei were visible in the GFP transduced hemisphere, suggesting that calpastatin 
prevented cell injury and striatal degeneration after co-injection with ATX-3 72Q. All 
the pictures were taken around the injection site area and show representative 
immunohistochemical stainings. Statistical significance was evaluated with Student’s t-
test (n = 4, **P < 0.01). SEM = standard error of the mean. 
Additionally, cresyl violet-stained sections further demonstrated a significant reduction 
in the number of shrunken hyperchromatic nuclei upon calpastatin overexpression (Fig. 
3E, F and H), indicating that calpain inhibition prevents cell injury and striatal 
degeneration induced by mutant ataxin 3 expression in the brain of adult mice. 
Calpastatin prevents nuclear translocation of mutant ataxin 3 in a dose-
dependent manner 
We further assessed the involvement of calpains in the pathogenesis of Machado–
Joseph disease by expressing mutant ataxin 3 in the mouse striatum upon three 
progressively increasing levels of calpastatin (Fig. 4), as follows: (i) wild-type animals; 
(ii) transgenic mice overexpressing calpastatin (Takano et al., 2005) and (iii) animals 
injected with AAV vectors encoding calpastatin.  
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Figure 4  
Inhibition of calpains prevents nuclear translocation and aggregation of mutant ATX-3 
in a dose dependent manner. Subcellular localization of mutant ataxin 3 (ATX-3 72Q, 
Ab 1H9, red) when co-injected with GFP (green, n = 4; A), in transgenic mice 
overexpressing calpastatin (Tg hCAST, n = 8; B) and when co-injected with calpastatin 
(CAST, Ab H300, green, n = 4; C and D). Nuclear marker (DAPI, blue) was used. As 
the levels of calpastatin increased (A to B and B to C), aggregation in the nucleus was 
prevented. (D) Calpastatin immunoreactivity (CAST, Ab H300, green) is lower in wild-
type (wt) and transgenic mice overexpressing calpastatin (Tg hCAST) than in AAV-2 
calpastatin injected mice. (E) Analysis of inclusion diameters showing double staining 
for mutant ataxin 3 with Ab 1H9 and GFP or calpastatin (***P < 0.0001). 
The mean diameter of mutant ataxin 3 intranuclear inclusions was reduced to 2.77 µm 
in transgenic animals (Fig. 4B and E), 1.4-fold smaller than the control, but 2-fold 
larger than the mean inclusion size when calpastatin levels were achieved by viral 
transduction (Fig. 4C and E). Fig. 4D shows the increasing calpastatin protein levels in 
transgenic mice overexpressing calpastatin and AAV2-calpastatin injected mice. 
These results suggest that a critical concentration of calpastatin is necessary to 
completely inhibit calpain activity in order to prevent mutant ataxin 3 translocation to 
the nucleus and aggregation. 
Inhibition of calpains reduces ataxin 3 proteolysis 
To investigate the mechanism by which calpain inhibition modified the subcellular 
localization of mutant ataxin 3, thereby preventing its nuclear localization, neuronal 
dysfunction and neurodegeneration, we performed western blot analysis of brain 
punches of mice subjected to the previously described experimental paradigm (Fig. 1E) 
but sacrificed at an earlier time point: 5 weeks post-injection. Striatal punches of non-
injected and ATX-3 27Q transduced hemispheres were used as controls. Importantly, 
two ataxin 3 fragments of ∼26 and ∼34 kDa were strongly detected in the brain 
hemispheres expressing mutant ataxin 3 (Fig. 5A; arrowheads), but sparingly and not 
detected, respectively, in those overexpressing wild-type and only expressing 
endogenous ataxin 3 (Fig. 5D); thus confirming in vivo that mutant ataxin 3 is cleaved 
into fragments that accumulate in the brain and that a wild-type fragment may be more 
rapidly degraded. Notably, inhibition of calpains activity, confirmed by a decreased 
immunolabelling of calpain-cleaved α-spectrin (Ab 38; Fig. 5E), a natural substrate of 
calpains, decreased by 39% the production of the ∼26 kDa mutant ataxin 3 fragment 
(Fig. 5A and F), which was also detected using a N-terminal antibody (Ab myc; Fig. 
5C) and a C-terminal antibody specific for the polyglutamine stretch (Ab 1C2; Fig. 5B). 
In addition, the formation of the ∼34 kDa fragment was also decreased by 17%, being 
this fragment only C-terminal and only generated from the mutant protein (Fig. 5G).  
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Figure 5  
Ataxin 3 proteolysis in the lentiviral mouse model of Machado–Joseph disease is 
decreased upon calpastatin overexpression. At 5 weeks post-injection, mice (n = 7) co-
injected bilaterally with mutant ataxin 3 (ataxin 3 72Q) and GFP (left hemisphere) or 
calpastatin (CAST, right hemisphere) were sacrificed and punches of the striatum were 
made to perform a western blot analysis with several antibodies to detect different 
epitopes of ataxin 3 protein: (A) Ab 1H9, which recognizes amino acids E214-L233; 
(B) Ab 1C2, specific for the polyglutamine stretch, present at the C-terminal of ataxin 3; 
and (C) Ab myc, which recognizes the myc tag located at the N-terminal of mutant 
ataxin 3. Two fragments of ∼26 and ∼34 kDa were detected (empty and shaded 
arrowheads, respectively). (D) Striatal punches of non-injected and ataxin 3 27Q 
transduced hemispheres. (E) Levels of calpastatin (CAST, antibody H300) and of 
calpain-cleaved α-spectrin (antibody 38) are also shown. (F and G) Densitometric 
quantification of ∼26 and ∼34 kDa fragments levels of mutant ataxin 3 relative to actin, 
shown in panel A (n = 7, *P = 0.05). The ∼26 kDa fragment is clearly detected by Ab 
1H9, Ab 1C2 and anti-myc in the mutant ataxin 3 sample, but faintly in the transgenic 
wild-type and not detected in the endogenous ataxin 3 sample. The ∼34 kDa fragment is 
only detected in the mutant ataxin 3 sample using Ab 1H9 and Ab 1C2. SEM = standard 
error of the mean. 
These results are in accordance with the ‘toxic fragment hypothesis’ and strongly 
support the idea that inhibition of ataxin 3 cleavage by calpains may be the basis of the 
calpastatin neuroprotective mechanism. 
Calpastatin is depleted from cells with mutant ataxin 3 intranuclear 
inclusions 
Progression of Machado–Joseph disease could be propelled by depletion of calpastatin, 
which would accelerate calpains dysregulation and lead to neurodegeneration. To 
investigate this hypothesis, we evaluated the immunoreactivity for calpastatin upon 
expression of mutant ataxin 3 in the previously described calpastatin transgenic mice 
(Takano et al., 2005). Whereas a strong calpastatin immunoreactivity was observed in 
the hemisphere transduced with lentiviral vectors encoding ATX-3 27Q, a significant 
reduction of calpastatin immunostaining by 18%, was observed in cells where mutant 
ataxin 3 inclusions were present (Fig. 6A–F and J). Interestingly, in Fig. 6F, the cell 
highlighted with an arrow, where no ataxin 3 inclusions were observed, presented a 
similar calpastatin immunolabeling to those transduced with ATX3 27Q, contrasting 
with the reduced immunostaining detected in the cells pointed with arrowheads with 
large ataxin 3 intranuclear inclusions.  
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Figure 6  
Calpastatin is depleted from cells with mutant ataxin 3 intranuclear inclusions. 
Transgenic mice overexpressing calpastatin (Tg hCAST) were injected bilaterally: wild-
type ataxin 3 (ataxin 3 27Q) in the left hemisphere and mutant ataxin 3 (ataxin 3 72Q) 
in the right hemisphere and were sacrificed 4 weeks post-injection for (A-F,J), 
immunohistochemistry and (G,K), western blot analysis (n = 6; H). (A–F) Fluorescence 
staining for ataxin 3 (Ab 1H9, red; A and D), and in B and E, calpastatin (CAST, Ab 
H300, green) and nuclear marker (DAPI, blue). (A–C) While cells infected with ataxin 
3 27Q presented a strong calpastatin immunoreactivity, when ataxin 3 72Q was injected 
(D–F), the cells in which intranuclear inclusions were present showed nearly no 
calpastatin immunolabelling. (F) Even in the same hemisphere, in opposition to the cell 
indicated with an arrow, the cells with intranuclear inclusions (indicated with arrow 
heads) did not overexpress calpastatin, suggesting that the endogenous calpain inhibitor 
was depleted upon mutant ataxin 3 expression. Western blot analysis with anti-
calpastatin antibody (Ab H300) revealed a decrease of calpastatin levels in mutant 
ataxin 3 transduced hemisphere compared with its contralateral hemisphere (G); and 
also in lysates obtained from dissected cerebella of a Machado–Joseph disease 
transgenic mouse model (n = 5; H) and from dentate nucleus of Patients O, W and K 
with Machado–Joseph disease (I). (J) Quantitative analysis of calpastatin 
immunoreactivity (n = 4, **P < 0.01). (K–M) Densitometric quantification of 
calpastatin levels, shown in panels G–I, respectively. MJD = Machado–Joseph disease; 
SEM = standard error of the mean. 
Calpastatin depletion was further confirmed by immunoblot analysis of brains from 
calpastatin transgenic mice (Fig. 6G and K). Calpastatin levels were reduced by 26% in 
the hemisphere where mutant ataxin 3 was overexpressed in comparison to the contra-
lateral hemisphere with wild-type ataxin 3 overexpression. 
To validate calpastatin depletion in Machado–Joseph disease we analysed calpastatin 
levels in patient post-mortem tissue and in a transgenic mouse model of the disease 
using western blot (Torashima et al., 2008; Oue et al., 2009). A dramatic 68% reduction 
of calpastatin levels was found in the transgenic mouse model, when compared with 
wild-type mice (Fig. 6H and L). Importantly, in human tissue we observed that 
calpastatin levels were reduced by 67, 25 and 7% in samples from dentate nucleus of 
three patients with Machado–Joseph disease compared with the control (Fig. 6I and M). 
These results indicate that upon mutant ataxin 3 expression, calpastatin is depleted, 
which may in turn increase calpain activity, ataxin 3 proteolysis, nuclear translocation, 
aggregation and toxicity, ultimately triggering or at least severely aggravating the 
pathogenesis of Machado–Joseph disease. 
Discussion 
In this work, we provide in vivo evidence that calpains are proteolytic enzymes involved 
in the pathogenesis of Machado–Joseph disease and that inhibition of calpains reduces 
cleavage of mutant ataxin 3, its translocation to the nucleus, aggregation in nuclear 
inclusions, neurotoxicity and neurodegeneration. 
The neurotoxicity associated with Machado–Joseph disease has been proposed to be 
derived from a mutant ataxin 3 cleavage fragment (Ikeda et al., 1996; Haacke et al., 
2006; Takahashi et al., 2008; Koch et al., 2011), which above a critical concentration 
becomes cytotoxic (Goti et al., 2004). Based on cell or in vitro models, mutant ataxin 3 
has been reported to be a substrate for caspases (Berke et al., 2004; Jung et al., 2009), 
subject to autolytic cleavage (Mauri et al., 2006) and a substrate for calpains (Haacke et 
al., 2007; Koch et al., 2011). An additional cleavage site was proposed in a mouse 
model, within the N-terminus of amino acid 190, which might be neither a caspase nor a 
calpain product (Colomer Gould et al., 2007). 
To clarify this issue, we overexpressed the endogenous calpain-specific inhibitor 
calpastatin in a lentiviral mouse model of Machado–Joseph disease and used transgenic 
mice over-expressing calpastatin (Takano et al., 2005). This approach overcomes the 
use of synthetic peptidic, peptide-mimetic and non-peptidic calpain inhibitors currently 
available, which have problems of specificity, metabolic stability, water-solubility 
and/or penetration through the blood–brain barrier (Higuchi et al., 2005). Instead of 
using the lentiviral model in the rat (Alves et al., 2008), here we generated an analogous 
model in C57BL/6J mice that allows comparison of results with those obtained in the 
transgenic mice overexpressing calpastatin, and to previous in vivo studies. 
As expected, upon mutant ataxin 3 expression, the expanded protein accumulated as 
intranuclear inclusions co-localizing with ubiquitin in the mouse brain (Fig. 2C and E–
G). A marked loss of DARPP-32 immunoreactivity and a large number of pyknotic 
nuclei were observed (Fig. 3), suggesting cell injury and neurodegeneration. In contrast, 
when mutant ataxin 3 was co-injected with calpastatin to specifically inhibit calpains, a 
robust and dose-dependent decrease in the size and number of C- and N-terminal ataxin 
3 inclusions, respectively, (Fig. 2A, B and K) was observed. In addition, the volume of 
the region depleted of DARPP-32 immunoreactivity and the number of pyknotic nuclei 
were significantly and robustly decreased (Fig. 3), indicating that calpain inhibition 
prevents cell injury and provides neuroprotection. 
Cleavage fragments of mutant ataxin 3, whose existence has been controversial, were 
clearly detected in vivo in this study. While we were finalizing this work, a study in 
patient-specific induced pluripotent stem cell-derived neurons also reported the 
formation of cleavage fragments of mutant ataxin 3 upon l-glutamate or NMDA (N-
methyl-d-aspartate) stimulus (Koch et al., 2011). The two studies are concordant on 
providing compelling evidence of the involvement of calpains in Machado–Joseph 
disease, but not on the trigger for calpain activation, as in our study, cleavage of mutant 
ataxin 3 occurred without overstimulation of glutamate receptors. 
Cleavage of mutant ataxin 3 (Fig. 5) might occur at amino acid 220 (Fig. 1), giving rise 
to two different fragments of similar molecular weight detected by Ab 1H9 (Fig. 5A), 
which recognizes the human ataxin 3 fragment from amino acids E214-L233, Ab myc 
(Fig. 5C), an antibody for a myc tag located at the N-terminal of the protein and Ab 1C2 
(Fig. 5B), an antibody specific for the polyglutamine stretch, present at ataxin 3 C-
terminal (Fig. 1F). A simultaneous cleavage at amino acids 60 and 260 proposed by 
Haacke et al. (2007) may lead to the final ∼26 kDa fragment, detected by Ab 1H9. 
Cleavage at amino acid 154 may generate a mutant C-terminal ∼34 kDa fragment only 
detected by Ab 1H9 (Fig. 5A) and Ab 1C2 (Fig. 5B), but not by Ab myc (Fig. 5C). 
These results support the toxic fragment hypothesis indicating that calpastatin promotes 
neuroprotection by decreasing mutant ataxin 3 fragment production, suggesting that the 
pathogenesis of Machado–Joseph disease is strongly associated with mutant ataxin 3 
proteolysis by calpains. As evidenced by the decreased cleavage of α-spectrin, a 
potential biomarker for neuronal cell injury (Liu et al., 2008) and ataxin 3 (Fig. 5A and 
E), upon calpastatin overexpression, proteolysis of other substrates might also be 
inhibited as well as other functions regulated by calpains under pathological conditions 
not addressed in our studies. Recent evidences suggest that not only the C-terminal 
fragment is cytotoxic (Ikeda et al., 1996; Goti et al., 2004), but that the non-
polyglutamine containing ataxin 3 N-terminus fragment is also toxic and may contribute 
to an impaired unfolded protein response in the pathogenesis of Machado–Joseph 
disease (Hubener et al., 2011). Our results show that calpastatin overexpression leads to 
a decrease of both fragments formation. Further evidence that calpastatin exerted 
neuroprotection may also be drawn from the subcellular localization of the ataxin 3 
species. 
Ataxin 3, when non-expanded, is enriched in the cytoplasm (Paulson et al., 1997a; 
Schmidt et al., 1998; Goti et al., 2004), but upon polyglutamine expansion the protein 
accumulates in the nucleus. This nuclear localization is required for the in vivo 
manifestation of Machado–Joseph disease neuropathology. Accordingly, transgenic 
mice with 148 CAGs but attached to a nuclear export signal only develop a milder 
phenotype with few inclusions (Bichelmeier et al., 2007). However, how ataxin 3 enters 
the nucleus under pathogenic conditions and forms aggregates is a matter of debate. It 
has been proposed that CK2-dependent phosphorylation determines cellular localization 
(Mueller et al., 2009) and that proteotoxic stress increases nuclear localization of ataxin 
3 (Reina et al., 2010), while other reports underline the importance of nuclear 
localization (NLS282) and nuclear export (NES 77 and 141) signals to ataxin 3 
intracellular localization (Antony et al., 2009; Macedo-Ribeiro et al., 2009). 
Accordingly, we found that the number of inclusions detected with the antibody 
targeting the N-terminal ataxin 3 was significantly lower than the amount found when 
using the 1H9 antibody (amino acids 221–224) in both GFP and calpastatin-transduced 
hemispheres. This suggests that the C-terminal fragment, including the nuclear 
localization signal and the polyglutamine stretch, is more prone to aggregation and 
accumulates in higher extension in the nucleus as compared to the N-terminal fragment 
carrying the nuclear export signal sequences (Schmidt et al., 1998; Goti et al., 2004; 
Koch et al., 2011; Walsh et al., 2005). Furthermore, our results show that proteolysis of 
mutant ataxin 3 by calpains is required for its translocation to the nucleus in a dose-
dependent manner (Fig. 4). As calpastatin levels increase, the diameter of mutant ataxin 
3 inclusions progressively decreases (Fig. 4A: 3.98 µm; B: 2.77 µm; and C: 1.40 µm). 
Our results suggest that calpains cleavage between the nuclear export signals and the 
nuclear localization signal discussed above may account for the enhanced transport of 
the C-terminal fragment simultaneously carrying the nuclear localization signal and the 
expanded polyglutamine tract of ataxin 3 from the cytoplasm to the nucleus. Altogether, 
calpain activity is required for mutant ataxin 3 translocation to the nucleus, and this 
effect is antagonized by the presence of calpastatin. 
Finally, our studies suggest that upon mutant ataxin 3 expression calpastatin is depleted 
(Fig. 6), in accordance to what was observed in models of Alzheimer’s disease, where 
the progression is propelled by a marked depletion of calpastatin, upstream of calpain 
activation (Rao et al., 2008). Calpastatin depletion was observed not only in the 
lentiviral mouse model, but also in a mouse model of Machado–Joseph disease 
(Torashima et al., 2008; Oue et al., 2009) and in human brain tissue. Rather than simply 
its consequence, we speculate that calpastatin depletion may progressively lead to 
calpain overactivation. Our results suggest that calpain activation promotes mutant 
ataxin 3 cleavage, which in turn translocates to the nucleus and aggregates, and that 
during this process calpastatin might also be cleaved, further contributing to calpain 
overactivation. This observation may also explain the larger diameter of mutant ataxin 3 
inclusions in transgenic mice overexpressing calpastatin than in mice infected with 
AAV2-calpastatin (Fig. 4). In this experiment, lower calpastatin overexpression levels 
may have been insufficient to overcome calpastatin depletion, and to inhibit and prevent 
nuclear aggregation. 
In conclusion, we established the connection in vivo between mutant ataxin 3 
proteolysis by calpains, fragment production and nuclear localization, which contributes 
to the elucidation of the pathogenic mechanism of Machado–Joseph disease. 
Furthermore, we show that calpastatin, the endogenous calpain-specific inhibitor, is able 
to block this mechanism, preventing nuclear translocation of mutant ataxin 3, 
consequent aggregation and nuclear toxicity. Therefore, these findings indicate that 
calpains are promising targets for therapeutic intervention in Machado–Joseph disease. 
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